title: Long-term respiratory follow-up of H1N1 infection.
abstract: BACKGROUND
  The first case of 2009 pandemic influenza A (H1N1) virus infection was documented in our Hospital on 10th August 2009.
  
  
  RESULTS
  Real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) testing was used to confirm the diagnosis. All patients were treated with oseltamivir from the first day of hospitalization. Upon admission 12/44 had local patchy shadowing in their chest x-ray and additionally antibiotic regimen was added to these patients as pneumonia was suspected based on clinical evidence. In total 44 patients were hospitalized 15/44 had asthma, 6/44 COPD, 5/44 leukemia. Lung function was evaluated with forced vital capacity, forced expiratory volume in 1 sec and diffused carbon monoxide upon discharge and every 3 months, until 6 months of observation was completed after discharge. The purpose of this retrospective cohort study was to evaluate whether influenza A (H1N1) had an impact on the respiratory capacity of the infected patients.
  
  
  CONCLUSIONS
  An improvement of pulmonary function tests was observed between the first two measurements, implicating an inflammatory pathogenesis of influenza A (H1N1) to the respiratory tract. This inflammation was not associated with the severity or clinical outcome of the patients. All patients had a mild clinical course and their respiratory capacity was stable between the second and third measurement, suggesting that the duration of respiratory inflammation was two months. Early treatment with antiviral agents and vaccination represent the mainstay of management.
authors.affiliation: Unit of Infectious Diseases, Democritus University Thrace, Dragana, 68100 Alexandroupolis, Greece. pzarog@hotmail.com
authors.forename: Paul
authors.initials: P
authors.lastname: Zarogoulidis
authors.forename: George
authors.initials: G
authors.lastname: Kouliatsis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Papanas
authors.forename: Dionysis
authors.initials: D
authors.lastname: Spyratos
authors.forename: Theodoros C
authors.initials: TC
authors.lastname: Constantinidis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kouroumichakis
authors.forename: Paschalis
authors.initials: P
authors.lastname: Steiropoulos
authors.forename: Maria
authors.initials: M
authors.lastname: Mabroudi
authors.forename: Dimitris
authors.initials: D
authors.lastname: Matthaios
authors.forename: Theodora
authors.initials: T
authors.lastname: Kerenidi
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Courcoutsakis
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Zarogoulidis
authors.forename: Efstratios
authors.initials: E
authors.lastname: Maltezos
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000998:Antiviral Agents / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification* / Q000472:pathogenicity*; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy / Q000473:pathology* / Q000821:virology*; D008168:Lung / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D053139:Oseltamivir / Q000008:administration & dosage; D018410:Pneumonia, Bacterial / Q000175:diagnosis / Q000188:drug therapy; D013902:Radiography, Thoracic; D012129:Respiratory Function Tests; D013997:Time Factors; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D053139:Oseltamivir